Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron Group PLC treats first patient in retinitis pigmentosa trial

The procedure involves a single injection of hRPC cells under the retina
ReNeuron Group PLC treats first patient in retinitis pigmentosa trial
RP leads to progressive loss of sight due to photoreceptor cells in the retina becoming damaged and eventually dying.

Stem cell specialist ReNeuron Group PLC (LON:RENE) has treated its first patient in a phaseI/II US trial of its retinitis pigmentosa (RP) cell therapy remedy.

The procedure, involving a single injection of hRPC cells under the retina, was conducted at Massachusetts Eye and Ear in Boston, a teaching affiliate of Harvard Medical School and a specialist in retinal degeneration. The patient was discharged from hospital that day.

RP leads to progressive loss of sight due to photoreceptor cells in the retina becoming damaged and eventually dying. 

ReNeuron’s Human Retinal Progenitor Cells (hRPCs) have shown an ability to protect the host retina from further degeneration and also potentially treat any of the genetic variants of RP.

Fifteen patients will be treated with  hRPC in the trial, the company’s first in the US. The hRPC programme has US fast-track status and Orphan Drug Designation in both the US and Europe.

ReNeuron aims to file for a Phase II/III clinical trial in the second half of 2017 dependent on how this trial goes.  

Olav Hellebo, ReNeuron’s chief executive said:  “Retinal degenerative diseases represent extremely attractive targets for cell therapy approaches and our programme targeting RP benefits from a number of key competitive advantages in terms of the potential mechanisms of action of our hRPC cells and the potential speed of clinical development to market for this programme.

“With the start of this study, we are also delighted to have commenced clinical development activities in the US, a major target market."

PhilW.jpg
Why Invest In ReNeuron Group Plc? Read More Here

Register here to be notified of future RENE Company articles
View full RENE profile View Profile

ReNeuron Group Plc Timeline

Newswire
February 15 2017

Related Articles

antibiotic.jpg
April 18 2017
Iclaprim is one of the next-generation of antibiotics and it will be used, initially at least, to treat acute bacterial skin and skin structure infections
Drugs
May 03 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use